Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of central nervous system disorders. Its product candidates include AXS-02, which is in Phase III trial for the treatment of complex regional pain syndrome, knee osteoarthritis, and chronic low back pain; and AXS-05 that is in Phase III trial for the treatment of resistant depression and agitation in patients with Alzheimer's disease. The company is also developing AXS-06 for the treatment of chronic pain disorders. Axsome Therapeutics, Inc. was founded in 2012 and is based in New York, New York.
http://www.priceseries.com/trade/AXSM-Axsome-Therapeutics-Inc-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2017061620170703.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments